Polymer microneedle for treating acute gout by inhibiting release of inflammatory factors and preparation method thereof

Abstract

The invention discloses a polymer microneedle for treating acute gout by inhibiting release of inflammatory factors and a preparation method thereof. According to the microneedle provided by the invention, a medicinal preparation which is wrapped by a nano material and contains an effective dose of serine protease inhibitor is embedded in a needle tip of the microneedle; and the medicinal preparation is prepared from the following components in parts by weight: 0.005-0.05 part of serine protease inhibitor, 0.05-0.15 part of sodium phosphate, 0.0025-0.025 part of mannitol and 0.005-0.025 part of sodium chloride. The microneedle disclosed by the invention can be directly attached to a sick part, and is simple and convenient; by means of nano material wrapping and slow release, the medicine can fully play a role, the better fixed-point and targeted treatment effect is achieved, and the medicine utilization rate is higher; and the problem that the serine protease inhibitor is difficult to act on the symptom part for a long time in systemic circulation is solved, and the problem caused by excessive use of the serine protease inhibitor in a systemic way is avoided.

Description

technical field [0001] The present application relates to the technical field of gout treatment, in particular to a polymer microneedle that inhibits the release of inflammatory factors to treat acute attacks of gout and a preparation method thereof. Background technique [0002] Gout is a common disease in the world. According to epidemiological statistics, the prevalence rate of hyperuricemia reported in Europe and the United States in the 1990s was 2%-24%, and the prevalence rate of hyperuricemia reported in the United States in 1993 was 10.1%. According to statistics in China in 2008, the overall prevalence rate of hyperuricemia was 13.2-21.04%. The total prevalence of gout around the world is between 0.13-15.3%, and the global annual incidence is between 0.20%-0.35%. The incidence of gout and hyperuricemia in European and American countries is significantly higher than that in other countries, and it is increasing year by year. Among them, the prevalence of gout patie...

AI Technical Summary

Problems solved by technology

[0012] However, the use of injections for transdermal administration may cause adverse side effects such as keratin hyperplasia, redness, swelling, and induration on the skin where frequent injections are required, and it will also bring strong pain and discomfort to the patient.

Although the recombinant AAT-Fc has strong efficacy, it still requires a relatively high dose to reach the effective concentration at the symptom site by subcutaneous injection through the systemic route.

These relatively high systemic doses of AAT-Fc can lead to non-specific immunosuppression, which increases infection rates and various adverse effects

These unfavorable factors limit the efficacy and wide application of AAT-Fc

Images